Biomind Labs Inc. announced a major strategic advancement in the development of BMND08, transitioning the program into FDA-directed activities using the Company's newly engineered nano-formulation drug-delivery platform, designed to support commercial-stage clinical trials in neuropsychiatric and neurodegenerative disorders. Following a Phase 2 trial that established a new benchmark in neurology with a 100% response rate in Alzheimer's-related mood disorders, Biomind is now introducing a proprietary nano-delivery technology for BMND08, engineered to deliver superior dosing precision, safety, absorption, and commercial-grade manufacturing scalability. Strengthened Biomind's Intellectual Property Position: Several third-party patent observations were filed with the patent office.

All third-party patent observations were successfully resolved. The patent application continues to progress in good standing. Biomind believes this outcome: Reinforces the novelty, inventiveness, and strategic importance of the proprietary nano-formulation.

Supports the competitive defensibility of BMND08 as it moves toward commercial-stage development. While the Company does not speculate on the identity or motives of the parties who submitted the observations, management views the outcome as an affirmation of the strength and unique nature of the underlying invention. The Company is now preparing the regulatory and technical prerequisites for the FDA to present the nanoformulation package, discuss pivotal trial design, define commercial-stage development requirements, and evaluate eligibility for expedited programs such as Breakthrough Therapy.

The Company also announces that it has granted an aggregate of 6,200,000 incentive stock options to certain directors, officers, and consultants to the Company. The options are exercisable at $0.35 per share and expire on November 3, 2030.